,

New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Crisis

SOUTH PLAINFIELD, N.J., May 2, 2017 /PRNewswire/ -- SANGUINATE™, the only investigational biopharmaceutical product currently in clinical development for the treatment of multiple comorbidities of sickle cell disease (SCD), is effective in returning red blood cells to a more normal morphology (shape) in patients experiencing vaso-occlusive crisis (VOC)...
,

Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO™

Unique activity Noted in Drug: Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities announced today that it has presented data on the toxicology, pharmacokinetic and pharmacodynamic profile of its novel anti-neutropenia drug, ANF-RHO.
,

Prolong Pharmaceuticals Hosts Workshop at the Society for Blood Advancement

Prolong Pharmaceuticals presented at the 2016 Society for Blood Advancement (SABM) meeting in Grand Rapids Michigan. The Workshop entitled Clinical Use of SANGUINATE in Patients for Whom Blood is Not an Option provided an overview of the use of SANGUINATE followed by the presentation of a case report of a patient who received SANGUINATE for life threatening anemia.
,

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America.

PROLONG PHARMACEUTICALS JOINS NEW SICKLE CELL DISEASE COALITION, ISSUES CALL TO ACTION TO IMPROVE TREATMENT AND CARE

Prolong Pharmaceuticals joins other leading patient advocacy groups, researchers, clinicians, policymakers, industry, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research, both in the United States and globally...

NY/NJ CEO Biotech Conference to Feature Prominent CEOs -- November 11 & 12, Prolong's President, Glenn Kazo, to present.

NY/NJ CEO is an off-the-record networking and educational forum for leading executives in life sciences, offering exclusive access to key decision makers who influence ...

ASCO 2015 publishes Prolong Pharmaceuticals, LLC’s e-Abstract of the Potential use of PEG – HbCO in severe anemia in 5 eIND patients

Abstract: Background: Patients who cannot receive blood transfusions in the presence of severe anemia can sustain significant morbidity and mortality. Religious beliefs and hemolytic reactions are the most common reasons for not transfusing a patient. Pegylated bovine carboxyhemoglobin (PEG-HbCO) has been used in 5 such patients

Prolong Pharmaceuticals Presents Data on Unique “Un-Sickling” In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE™

SOUTH PLAINFIELD, NJ, April 14, 2015 /PRNewswire/ -- Prolong announced today that it had presented data on its flagship product SANGUINATE, reporting its novel ability to rapidly reverse sickling of human red blood cells...

Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA

SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- Prolong announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its flagship product SANGUINATE...

Prolong Expands Operations (& Potential for Success)

Prolong recently announced the expansion of its South Plainfield, New Jersey, biologics processing facility, adding 24,000 square feet in a move that essentially doubles its original manufacturing capacity to 48,000 square feet...